MBK Healthcare Management Pte Ltd (“MHM”), a wholly owned subsidiary of Mitsui & Co., Ltd. (“Mitsui”) has supported Mitsui’s participation in a Series D investment in Mirxes Holding Company Limited (“Mirxes”), a leading, Singapore-based biotechnology company specializing in RNA-powered disease early detection. This investment underscores Mitsui and MHM’s commitment to supporting innovative technologies that have the potential to revolutionize healthcare and improve patient outcomes worldwide.

​

Mirxes is at the forefront of developing ground-breaking RNA-based diagnostic tools that enable early detection of various diseases, including cancers and infectious diseases. By leveraging the power of RNA technology, Mirxes has developed a platform capable of detecting disease-related biomarkers at an early stage, providing healthcare professionals with crucial information for timely intervention and personalized treatment strategies.

​

Mitsui and MHM believe that Mirxes’s cutting-edge technology has the potential to transform disease early detection and aligns with Mitsui’s commitment to investing in transformative technologies that improve patient care and healthcare outcomes. MHM aims to facilitate partnerships between Mitsui’s network and Mirxes, to improve access, distribution, and adoption of such innovative products globally.

​

MHM was established in 2016 as Mitsui’s dedicated healthcare operating platform. As the largest shareholder of IHH Healthcare Berhad (IHH, KLSE: 5225, SGX: Q0F), a leading premium healthcare provider operating 80 hospitals in 10 countries with more than 15,000 licensed beds, MHM’s mission is to create long-term value and to grow the portfolio within the healthcare ecosystem of Mitsui.